Sionna Therapeutics Stock Price, News & Analysis

Sionna Therapeutics presented promising preclinical data at the 48th European Cystic Fibrosis Conference demonstrating that their dual combination therapies achieve full CFTR correction in CF models. The company's NBD1 stabilizers (SION-719 and SION-451), when combined with complementary modulators (SION-2222 and SION-109), showed significant potential in treating cystic fibrosis. Key findings revealed that both SION-719 and SION-451 increase NBD1 stability by 16°C and achieve wild-type level corrections when combined with other modulators. Sionna plans to advance SION-719 to Phase 2a trials as an add-on to standard care, while SION-451 will proceed to Phase 1 trials in dual combinations. Both trials are set to begin in H2 2025, with results expected by mid-2026.

Sionna Therapeutics announced positive Phase 1 data for its NBD1 stabilizers SION-719 and SION-451 in treating cystic fibrosis. Both compounds demonstrated favorable safety profiles and achieved target pharmacokinetic concentrations in healthy volunteers. SION-719 will advance to Phase 2a proof-of-concept trial as an add-on to standard care, while SION-451 will proceed to Phase 1 combination trial. The trials involved 100 subjects for SION-719 and 110 for SION-451, with both drugs showing general tolerability and no serious adverse events. Both compounds can be administered twice daily and showed potential for clinical benefit. The company plans to initiate next-phase trials in H2 2025, with topline data expected by mid-2026. This development supports Sionna's goal of developing novel NBD1-led dual combinations to transform CF treatment.

Sionna Therapeutics (NASDAQ: SION), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cystic fibrosis (CF), has announced its participation in the Goldman Sachs 46th Annual Healthcare Conference. The company's management will engage in a fireside chat on June 11th, 2025, at 8:00 a.m. ET in Miami, Florida. The presentation will be accessible via live webcast on Sionna's investor relations website, with a replay available afterward. Sionna's mission centers on developing novel medicines that aim to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, potentially transforming the current CF treatment landscape.

Sionna Therapeutics (NASDAQ: SION) reported Q1 2025 financial results and provided pipeline updates for its cystic fibrosis (CF) treatments. The company completed Phase 1 dosing for its NBD1 stabilizers SION-719 and SION-451, with both compounds showing favorable tolerance. Following its successful upsized IPO in February 2025 that raised $219 million gross proceeds, Sionna maintains a strong cash position of $354.7 million, expected to fund operations into 2028. The company reported a Q1 2025 net loss of $16.5 million. Key upcoming milestones include Phase 1 topline data this quarter, initiation of a Phase 2a proof-of-concept trial, and at least one dual combination MAD trial in H2 2025, with topline data for both anticipated in mid-2026.

Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has announced its upcoming participation at The Citizens Life Sciences Conference.

The company's management will deliver a presentation on Wednesday, May 7, 2025, at 12:30 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the "Events" section of Sionna's investor relations website at investors.sionnatx.com.

Sionna's mission centers on revolutionizing CF treatment by developing new medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The presentation recording will remain accessible on the company's website for 90 days following the event.

Sionna Therapeutics (SION) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its cystic fibrosis (CF) treatment programs. The company completed Phase 1 MAD dosing for SION-451 and plans the final MAD cohort for SION-719, with both compounds showing encouraging tolerability profiles. Interim data indicates potential clinical benefits for CF patients, with topline data expected in H1 2025.

The company successfully completed an upsized IPO raising $219 million in gross proceeds, extending their cash runway into 2028. Financial results show R&D expenses of $57.3 million and G&A expenses of $13.3 million for 2024, with a net loss of $61.7 million. The company plans to initiate NBD1 Phase 2a proof-of-concept trials and combination MAD trials in H2 2025, with topline data anticipated in mid-2026.

Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cystic fibrosis (CF), has announced its participation in the 45th Annual TD Cowen Health Care Conference. The company's management will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET.

The presentation will be accessible through a live webcast on the company's investor relations website in the 'Events' section at investors.sionnatx.com. Interested parties who cannot attend the live presentation will have access to a replay, which will remain available for 90 days following the event.

Sionna's mission centers on revolutionizing CF treatment by developing new medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has successfully completed its upsized initial public offering (IPO). The company sold 12,176,467 shares of common stock at $18.00 per share, including 1,588,234 additional shares from the full exercise of the underwriters' option.

The IPO generated gross proceeds of approximately $219.2 million, before deducting underwriting discounts, commissions, and offering expenses. Trading of the shares began on the Nasdaq Global Market on February 7, 2025, under the ticker symbol 'SION'. The offering was jointly managed by Goldman Sachs & Co. , TD Cowen, Stifel, and Guggenheim Securities as book-running managers.

Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has announced the pricing of its upsized initial public offering. The company is offering 10,588,233 shares of common stock at $18.00 per share, with an additional 30-day option for underwriters to purchase up to 1,588,234 shares.

Trading is scheduled to begin on the Nasdaq Global Market on February 7, 2025, under the ticker symbol 'SION'. The offering, expected to close on February 10, 2025, aims to raise approximately $191 million in gross proceeds before deducting expenses. Goldman Sachs & Co. , TD Cowen, Stifel, and Guggenheim Securities are serving as joint book-running managers for the IPO.